Eli Lilly obesity drug retatrutide clears late-stage trial, nears approval

Eli Lilly said its experimental obesity drug retatrutide delivered one of the strongest late-stage results yet seen in the weight-loss race, with the highest dose producing 28.3% mean weight loss, or 70.3 pounds, over 80 weeks in adults with obesity or overweight and at least one weight-related comorbidity, but no diabetes.

The company announced the TRIUMPH-1 topline results on May 21, 2026, from a Phase 3 trial that enrolled 2,339 participants and tested 4 mg, 9 mg, 12 mg and placebo. Lilly said 45.3% of patients on the 12 mg dose lost at least 30% of their body weight, 65.3% reached a body mass index below 30, and 37.5% of those who started with class 3 obesity dropped below that threshold. In a blinded extension that followed a subgroup for 104 weeks, patients with a baseline BMI of 35 or above lost 30.3% on average, or 85.0 pounds.

Retatrutide is a first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, putting it in a different category from the current injections and pills from Eli Lilly and Novo Nordisk that have dominated the market. Lilly said the 4 mg dose produced 19.0% weight loss at 80 weeks, with a lower observed discontinuation rate due to adverse events than placebo, while about 11% of people on the highest dose stopped because of side effects. The company also said the trial improved waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure and high-sensitivity C-reactive protein.

The results sharpen the competition around what counts as a meaningful obesity drug. Lilly’s lead investigator, Ania Jastreboff of Yale School of Medicine and the Yale Obesity Research Center, said every dose produced clinically meaningful weight reduction and that people with severe obesity on the highest dose lost about 30% of their body weight over two years. That kind of efficacy could raise expectations for future drugs and put added pressure on regulators, clinicians and insurers to decide whether greater weight loss offsets higher rates of nausea, diarrhea and other gastrointestinal effects that have marked the class.

The question now is not only whether retatrutide reaches approval, but what happens if it does. Another effective entrant could ease strain on a market where demand has outpaced supply, broaden access if insurers treat stronger results as worth covering, and move obesity care closer to a standard in which sustained double-digit weight loss is expected rather than exceptional. Lilly has already shown the drug’s momentum, with phase 2 data in 2023 reaching 24.2% mean weight loss at 48 weeks and March 2026 diabetes results showing A1C reductions of 1.7% to 2.0% alongside 16.8% weight loss at the 12 mg dose.